We assist in monitoring the progression of neurodegenerative and demyelinating diseases.
We offer artificial intelligence (AI) solutions for advanced assessment and analysis of brain MRI studies.
WHO estimates
Our mission
We develop innovative solutions based on artificial intelligence (AI) for advanced assessment and analysis of brain MRI studies. This is our response to the growing demand for effective tools supporting the diagnosis and monitoring of the course of neurodegenerative and demyelinating diseases.
- 1
Patients with dementia
World Health Organization (WHO) estimates that the number of people living with dementia (with Alzheimer's disease being the most common form) is currently around 50 million worldwide, with nearly 10 million new cases every year.
- 2
Multiple Sclerosis
Multiple sclerosis (MS), affects approximately 2.8 million people worldwide (with a higher prevalence among young women), requires long-term medical surveillance and treatment. The disease significantly diminishes the quality of life for both patients and their families, especially as it progresses to severe disability.
Impact of Hetalox
Our comprehensive analysis system is needed to enable:
Early detection of diseases
accurate and fast disease detection and screening to identify patients susceptible to diseases,
Monitoring disease progression
objective analysis and long-term monitoring to provide necessary information for selecting appropriate treatment methods,
Support for treatment decisions
immediate modification of therapy when necessary,
Improving quality of life
reduction of the social impact of the disease and improvement of people's quality of life worldwide.
Contact us
If you are interested in our offer, cooperation, have questions or want to learn more about our solutions, please contact us.